Baclon-5 Tablet: Each tablet contains Baclofen BP 5 mg Tablet.
Baclon Tablet: Each tablet contains Baclofen BP 10 mg Tablet.
Baclofen is indicated to alleviate the spasms and associated pain, clonus, muscle rigidity and to improve the mobility in-
Chronic severe spasticity associated with variety of conditions like multiple sclerosis, spinal cord lesions
Muscle spasm of cerebral origin especially due to infantile cerebral palsy
Cerebrovascular accidents or in neoplastic and degenerative brain disease.
Baclofen is also indicated as in adjunct management of neurogenic bladder, in management of refractory trigeminal neuralgia.
Known hypersensitivity to Baclofen or to any of the ingredients.
Dosage & Administration
Adults: The optimum dosage generally ranges from 30 mg to 80 mg in 3 divided doses daily. Treatment should be always initiated with small, gradually increasing dosages of Baclofen. Therefore, treatment should be started with doses of 5 mg three times daily, increasing every 3 days by 5 mg 3 times daily until an optimum response is achieved. Up to 200 mg daily dose has been used for the control of severe spasticity in patients with spinal cord lesions although doses of more than 100 mg per day are not generally recommended.
Child: Treatment should usually be started with a very low dose, e.g. 0.3 mg/Kg daily in 4 divided doses. The dosage should be raised cautiously, at about 1 to 2 week intervals, until it becomes sufficient for the child\'s individual requirements. The recommended daily maintenance doses are: 12 months to 2 years: 10 to 20 mg; 2 to 6 years: 20 to 30 mg; 6 to 10 years: 30 to 60 mg.
Renal Impairment: Doses of Baclofen should be reduced in renal impairment or in patients undergoing chronic haemodialysis. Daily dose of 5 mg by mouth has been suggested for them.
If no benefit is apparent within 6 weeks of achieving the maximum dosage, therapy should probably be gradually withdrawn over at least 1-2 weeks.
Adverse effects associated with Baclofen are often transient and dose-related. They may be minimized by increasing doses gradually or controlled by a reduction in dosage. The most common adverse effects include drowsiness, nausea, dizziness, lassitude, lightheadedness, confusion, fatigue, muscular pain and weakness, and hypotension. Other adverse effects include euphoria, hallucinations, depression, headache, tinnitus, convulsions, paraesthesias, slurred speech, dry mouth, taste alterations, vomiting, diarrhoea or constipation, ataxia, nystagmus, tremors, insomnia, visual disturbances, skin rashes, pruritus, increased sweating, urinary disturbances, respiratory or cardiovascular depression, blood sugar changes, alterations in liver function values, and a paradoxical increase in spasticity. Problems with erection and ejaculation have also been reported with intrathecal Baclofen; these are usually reversible on withdrawal of therapy. Stopping Baclofen abruptly may result in a withdrawal syndrome. Epilepsy, progressing to status epilepticus, has been associated with the use of Baclofen in a patient who had no previous history of seizures.
Baclofen stimulates gastric acid secretion and should be used with caution in patients with a history of peptic ulcer and avoided in those with active peptic ulcer disease. It should also be used with caution in patients with severe psychiatric disorders or epilepsy or convulsive disorders since these disorders may be exacerbated by Baclofen. Liver function should be monitored in patients with liver disease; patients with renal impairment need a reduced dose. Baclofen should be used with caution in patients with respiratory impairment. Observations of increased blood sugar concentrations suggest caution in patients with diabetes mellitus. Care is also required in the elderly, in whom adverse effects may be more common, and in patients with cerebrovascular disease (who tolerate Baclofen poorly). It should be used with caution in patients who use their spasticity to maintain posture or to increase function. Urine retention may be exacerbated in patients with hypertonic bladder sphincters. Baclofen may cause drowsiness; patients affected should not drive or operate machinery. Abrupt withdrawal of Baclofen may result in a withdrawal syndrome and exacerbation of spasticity; dosage should be reduced gradually over at least 1 to 2 weeks, or longer if symptoms occur. Baclofen is considered to be unsafe in patients with porphyria because it has been shown to be porphyrinogenic in in-vitro systems.
Neonates: No information is available on the use of the drug in the neonates.
Breast feeding: The concentrations of Baclofen found in breast milk are small and UK licensed product information states that no undesirable effects are to be expected in breast-fed infants. The American Academy of Pediatrics also considers that Baclofen is usually compatible with breast feeding; no adverse effects have been seen in breast-feeding infants whose mothers were receiving Baclofen.
Pregnant Woman: The safety of Baclofen in pregnancy has not yet been established. Potential benefits should be weighed against possible hazards.
The elderly: Elderly patients on Baclofen appear to be more likely to experience adverse effects such as drowsiness. In elderly patients with cerebrovascular insufficiency, care is required as Baclofen may have hypotensive effects.
Alcohol and other CNS depressants may exacerbate the CNS effects of Baclofen and should be avoided; severe aggravation of hyperkinetic symptoms may possibly occur in patients taking lithium. There may be increased weakness if Baclofen is given to patients taking a tricyclic antidepressant and there may be an increased hypotensive effect if it is given to patients receiving antihypertensive therapy. Ibuprofen and other drugs that produce renal insufficiency may reduce Baclofen excretion leading to toxicity. Baclofen may be used in conjuction with Diazepam and other benzodiazepines.
Baclon-5 Tablet: Each box containing 5 X 10 tablets in blister strips.
Baclon Tablet: Each box containing 3 X 10 tablets in blister strips.